Second-line agents for glycemic control for type 2 diabetes: Are newer agents better?

Diabetes Care

Volumn 37, Issue 5, 2014, Pages 1338-1345

  Zhang, Yuanhui ^a   McCoy, Rozalina G ^b   Mason, Jennifer E ^c   Smith, Steven A ^b   Shah, Nilay D ^b,d   Denton, Brian T ^e  

^a NORTH CAROLINA STATE UNIVERSITY   (United States)

^b MAYO CLINIC   (United States)

^c UNIVERSITY OF VIRGINIA   (United States)

^d OPTUM   (United States)

^e UNIVERSITY OF MICHIGAN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDIABETIC AGENT; DIPEPTIDYL PEPTIDASE IV INHIBITOR; GLUCAGON LIKE PEPTIDE 1 RECEPTOR AGONIST; INSULIN; METFORMIN; SULFONYLUREA;

ADULT; AMPUTATION; ARTICLE; BLINDNESS; CEREBROVASCULAR ACCIDENT; CONGESTIVE HEART FAILURE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DRUG EFFICACY; FEMALE; GLYCEMIC CONTROL; HEART INFARCTION; HUMAN; ISCHEMIC HEART DISEASE; KIDNEY FAILURE; MALE; MONOTHERAPY; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; QUALITY OF LIFE; RISK BENEFIT ANALYSIS; UNITED STATES;

EID: 84899126930     PISSN: 01495992     EISSN: 19355548     Source Type: Journal    
DOI: 10.2337/dc13-1901     Document Type: Article

References (40)

1. Centers for Disease Control and Prevention. National Diabetes Fact Sheet: National Estimates and General Information on Diabetes and Prediabetes in the United States, 2011. Atlanta, GA, Department of Health and Human Services, Centers for Disease Control and Prevention, 2011
2. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993;329: 977-986
3. Nathan DM, Cleary PA, Backlund JY, et al.; Diabetes Control and Complications Trial/ Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Study Research Group. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med 2005;353:2643-2653
4. Ohkubo Y, Kishikawa H, Araki E, et al. Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year study. Diabetes Res Clin Pract 1995;28:103-117
5. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998;352:837-853
6. Stratton IM, Adler AI, Neil HA, et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 2000;321:405-412 (Pubitemid 30609442)
7. Ismail-Beigi F, Craven T, Banerji MA, et al.; ACCORD trial group. Effect of intensive treatment of hyperglycaemia on microvascular outcomes in type 2 diabetes: an analysis of the ACCORD randomised trial. Lancet 2010;376:419-430
8. Patel A, MacMahon S, Chalmers J, et al.; ADVANCE Collaborative Group. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 2008;358:2560-2572 (Pubitemid 351831357)
9. Duckworth W, Abraira C, Moritz T, et al.; VADT Investigators. Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med 2009;360:129-139
10. Garber AJ, Abrahamson MJ, Barzilay JI, et al.; American Association of Clinical Endocrinologists. AACE comprehensive diabetes management algorithm 2013. Endocr Pract 2013;19: 327-336
11. American Diabetes Association. Standards of medical care in diabetes - 2013. Diabetes Care 2013;36(Suppl. 1):S11-S66
12. Riethof M, Flavin PL, Lindvall B, et al.; Institute for Clinical Systems Improvement. Diagnosis and management of type 2 diabetes mellitus in adults [internet], 2012. Available from http://bit.ly/diabetes0412. Accessed 27 May 2013
13. Alexander GC, Sehgal NL, Moloney RM, Stafford RS. National trends in treatment of type 2 diabetes mellitus, 1994-2007. Arch Intern Med 2008;168:2088-2094
14. American Diabetes Association. Economic costs of diabetes in the U.S. in 2012. Diabetes Care 2013;36:1033-1046
15. Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 2008;359:1577-1589
16. Bennett WL, Wilson LM, Bolen S, et al. Oral diabetes medications for adults with type 2 diabetes: an update. In Comparative Effectiveness Reviews, No. 27. Rockville, MD, U.S. Agency for Healthcare Research and Quality, 2011
17. CDC Diabetes Cost-effectiveness Group. Cost-effectiveness of intensive glycemic control, intensified hypertension control, and serum cholesterol level reduction for type 2 diabetes. JAMA 2002;287:2542-2551
18. Chen J, Alemao E, Yin D, Cook J. Development of a diabetes treatment simulation model: with application to assessing alternative treatment intensification strategies on survival and diabetes-related complications. Diabetes Obes Metab 2008;10(Suppl. 1):33-42
19. Centers for Disease Control and Prevention. Age at diagnosis of diabetes among adult incident cases aged 18-79 years [internet]. Available from http://www.cdc.gov/diabetes/statistics/incidence-national.htm. Accessed 28 May 2013
20. Kramer H, Cao G, Dugas L, Luke A, Cooper R, Durazo-Arvizu R. Increasing BMI andwaist circumference and prevalence of obesity among adults with Type 2 diabetes: the National Health and Nutrition Examination Surveys. J Diabetes Complications 2010;24:368-374
21. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive Summary of the Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001;285:2486-2497
22. Sinha A, Rajan M, Hoerger T, Pogach L. Costs and consequences associated with newer medications for glycemic control in type 2 diabetes. Diabetes Care 2010;33:695-700
23. Yeaw J, Lee WC, Aagren M, Christensen T. Cost of self-monitoring of blood glucose in the United States among patients on an insulin regimen for diabetes. J Manag Care Pharm 2012;18:21-32
24. DeFronzo RA, Stonehouse AH, Han J, Wintle ME. Relationship of baseline HbA1c and efficacy of current glucose-lowering therapies: a metaanalysis of randomized clinical trials. Diabet Med 2010;27:309-317
25. Hermann LS, Scherstén B, Bitzén PO, Kjellström T, Lindgärde F, Melander A. Therapeutic comparison of metformin and sulfonylurea, alone and in various combinations. A double-blind controlled study. Diabetes Care 1994;17:1100-1109 (Pubitemid 24307443)
26. Russell-Jones D, Cuddihy RM, Hanefeld M, et al.; DURATION-4 Study Group. Efficacy and safety of exenatide once weekly versus metformin, pioglitazone, and sitagliptin used as monotherapy in drug-naive patients with type 2 diabetes (DURATION-4): a 26-week double-blind study. Diabetes Care 2012;35: 252-258
27. Moretto TJ, Milton DR, Ridge TD, et al. Efficacy and tolerability of exenatide monotherapy over 24 weeks in antidiabetic drug-naive patients with type 2 diabetes: a randomized, double-blind, placebo-controlled, parallelgroup study. Clin Ther 2008;30:1448-1460
28. Shorr RI, Ray WA, Daugherty JR, Griffin MR. Incidence and risk factors for serious hypoglycemia in older persons using insulin or sulfonylureas. Arch Intern Med 1997;157: 1681-1686 (Pubitemid 27327403)
29. Puterman ML. Markov Decision Processes: Discrete Stochastic Dynamic Programming. Hoboken, NJ, John Wiley & Sons, Inc., 1994
30. Siegel JE, Weinstein MC, Russell LB, Gold MR; Panel on Cost-Effectiveness in Health and Medicine. Recommendations for reporting cost-effectiveness analyses. JAMA 1996;276: 1339-1341 (Pubitemid 26346934)
31. National Committee for Quality Assurance (NCQA). HEDIS 2009 Volume 2: Technical Update [Internet]. Available from http://www.ncqa.org/portals/0/ PolicyUpdates/HEDIS%20Technical%20Updates/2009-Vol2-Technical-Update.pdf. Accessed 20 May 2013
32. Arias E. United States life tables, 2008. In National Vital Statistics Reports. Hyattsville, MD, National Center for Health Statistics, 2012
33. Clarke PM, Gray AM, Briggs A, et al.; UK Prospective Diabetes Study (UKDPS) Group. A model to estimate the lifetime health outcomes of patients with type 2 diabetes: the United Kingdom Prospective Diabetes Study (UKPDS) Outcomes Model (UKPDS no. 68). Diabetologia 2004;47:1747-1759 (Pubitemid 40022410)
34. Centers for Disease Control and Prevention. Deaths, percent of total deaths, and death rates for the 15 leading causes of death in 10-year age groups, by race and sex: United States, 1999-2010 [internet]. Available from http://www.cdc.gov/nchs/nvss/mortality/lcwk2.htm. Accessed 20 May 2013
35. U.S. Bureau of Labor Statistics. CPI inflation calculator [internet]. Available from http://www.bls.gov/data/in fl ation-calculator.htm. Accessed 20 May 2013
36. Bagust A, Hopkinson PK,Maier W, Currie CJ. An economic model of the long-term health care burden of Type II diabetes. Diabetologia 2001;44:2140-2155 (Pubitemid 34015466)
37. Eastman RC, Javitt JC, Herman WH, et al. Model of complications of NIDDM. I.Model construction and assumptions. Diabetes Care 1997; 20:725-734 (Pubitemid 27202520)
38. Zhou H, Isaman DJ, Messinger S, et al. A computer simulation model of diabetes progression, quality of life, and cost. Diabetes Care 2005;28:2856-2863 (Pubitemid 43942915)
39. Singh S, Chang HY, Richards TM, Weiner JP, Clark JM, Segal JB. Glucagonlike peptide 1-based therapies and risk of hospitalization for acute pancreatitis in type 2 diabetes mellitus: a population-based matched case-control study. JAMA Intern Med 2013;173:534-539
40. Dore DD, Seeger JD, Arnold Chan K. Use of a claims-based active drug safety surveillance system to assess the risk of acute pancreatitis with exenatide or sitagliptin compared to metformin or glyburide. Curr Med Res Opin 2009;25:1019-1027